Does Weight Impact Anidulafungin Pharmacokinetics?

Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients are lacking. We determined anidulafungin pharmacokinetics (100-mg single dose) in eight morbidly obese subjects (body mass index >40 kg/m(2)). Anidulafungin exposure was on average 32.5 % lower compared wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lempers, Vincent J., van Rongen, Anne, van Dongen, Eric P., van Ramshorst, Bert, Burger, David M., Aarnoutse, Rob E., Knibbe, Catherijne A., Brüggemann, Roger J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021753/
https://www.ncbi.nlm.nih.gov/pubmed/27142114
http://dx.doi.org/10.1007/s40262-016-0401-8
Descripción
Sumario:Bodyweight has been shown to influence anidulafungin exposure, but data from obese patients are lacking. We determined anidulafungin pharmacokinetics (100-mg single dose) in eight morbidly obese subjects (body mass index >40 kg/m(2)). Anidulafungin exposure was on average 32.5 % lower compared with the general patient population, suggesting dose increases may be required in this population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40262-016-0401-8) contains supplementary material, which is available to authorized users.

Ejemplares similares